<DOC>
	<DOCNO>NCT00492687</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Drugs use chemotherapy , temozolomide carboplatin , work different way stop growth tumor cell , either kill cell stop dividing . Tamoxifen may make tumor cell sensitive radiation therapy chemotherapy . Giving radiation therapy together temozolomide , tamoxifen , carboplatin may kill tumor cell . PURPOSE : This phase II trial study side effect well give radiation therapy together temozolomide , tamoxifen , carboplatin work treat patient malignant glioma .</brief_summary>
	<brief_title>Radiation Therapy , Temozolomide , Tamoxifen , Carboplatin Treating Patients With Malignant Gliomas</brief_title>
	<detailed_description>OBJECTIVES : - Determine progression-free overall survival patient supratentorial malignant glioma ( WHO grade III IV ) receive radiotherapy concurrent adjuvant temozolomide , tamoxifen citrate , carboplatin . - Determine acute delay treatment-related toxicity patient . - Determine tumor response patient postoperative measurable disease . OUTLINE : This open-label , pilot study . - Induction therapy : Patients receive oral temozolomide twice daily oral tamoxifen citrate twice daily day 1-42 carboplatin IV 60 minute day 1 , 8 , 15 , 22 , 29 , 36 . Patients also receive radiotherapy day 1-5 week 1-6 . - Consolidation therapy : Beginning 4 week completion induction therapy , patient receive temozolomide , tamoxifen citrate , carboplatin induction therapy . Treatment repeat every 8 week 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm glioblastoma multiforme and/or anaplastic astrocytoma Supratentorial tumor No welldifferentiated astrocytoma glioma oligodendroglial component No multifocal glioma Has undergone surgery within past 6 week No recurrent glioblastoma multiforme PATIENT CHARACTERISTICS : ECOG performance status 02 Neurological functional status 02 Life expectancy &gt; 12 week ANC ≥ 1,200/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9 g/dL Serum creatinine ≤ 1.5 time upper limit normal ( ULN ) Blood urea nitrogen ≤ 1.5 time ULN Total direct bilirubin ≤ 3 time ULN AST ALT ≤ 3 time ULN Alkaline phosphatase ≤ 3 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study completion No malignancy within past 3 year , except carcinoma situ cervix nonmelanoma skin cancer No acquire immune deficiency syndrome ( AIDS ) No major medical illness psychiatric impairment would preclude study compliance PRIOR CONCURRENT THERAPY : No prior radiotherapy head neck No concurrent therapy tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult glioblastoma</keyword>
</DOC>